Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Maravilla LLC is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These active cases are distributed among 2 distinct examiners and 2 distinct art units. This arrangement indicates that the company's current legal challenges are being addressed by different specialists within the USPTO.
The busiest examiner for this portfolio is BAUER, BRIANNA LEE, who is currently overseeing 1 pending office action. Given that the total count of pending actions is 2 and there are distinct examiners, each examiner is responsible for a case. This ratio between examiners and pending actions suggests a decentralized prosecution environment where each matter is handled in isolation.
The use of 2 distinct art units reflects a separation of the pending office actions into different technical examination groups. Practitioners should be aware that because each of the distinct examiners has only 1 pending action, there is no opportunity to consolidate arguments or streamline communications across multiple files with a single official. Each of the pending office actions will require a unique approach based on the specific examiner's requirements.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAUER, BRIANNA LEE | 1 | 66.7% | +0.0% |
| COLEMAN, BRENDA LIBBY | 1 | 74.8% | +15.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18388554 | Pre And Post Natal Compositions Including Carotenoids | COLEMAN, BRENDA LIBBY | 3d overdue |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18394591 | COMPOSITIONS AND METHODS FOR IMPROVING CARDIOVASCULAR HEALTH | BAUER, BRIANNA LEE | 1623 | §103DP | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18388554 | Pre And Post Natal Compositions Including Carotenoids | COLEMAN, BRENDA LIBBY | 1624 | §112 | Non-Final OA | 3d overdue | Pending | Nov 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMaravilla LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Brianna Lee Bauer has the most, with 1 of Maravilla LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
